Thomas Albini, MD, discusses the factors that drive his decision to reimplant Retisert®. When treating chronic noninfectious posterior uveitis, reimplantation of RETISERT® may be needed after 2.5-3 years to help ensure management of the disease.
RETISERT® (ﬂuocinolone acetonide intravitreal implant) 0.59 mg is a corticosteroid indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye.
Click here for full prescribing information on RETISERT®
®/™ are trademarks of Bausch & Lomb Incorporated or its affiliates.
Any other products/brand names are trademarks of the respective owners.
©Bausch & Lomb Incorporated. All rights reserved. RET.0036.USA.17